Deepak Gurbani

2.4k total citations · 1 hit paper
25 papers, 1.8k citations indexed

About

Deepak Gurbani is a scholar working on Molecular Biology, Cancer Research and Materials Chemistry. According to data from OpenAlex, Deepak Gurbani has authored 25 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 5 papers in Cancer Research and 5 papers in Materials Chemistry. Recurrent topics in Deepak Gurbani's work include Melanoma and MAPK Pathways (6 papers), Protein Kinase Regulation and GTPase Signaling (5 papers) and Protein Degradation and Inhibitors (3 papers). Deepak Gurbani is often cited by papers focused on Melanoma and MAPK Pathways (6 papers), Protein Kinase Regulation and GTPase Signaling (5 papers) and Protein Degradation and Inhibitors (3 papers). Deepak Gurbani collaborates with scholars based in United States, India and South Korea. Deepak Gurbani's co-authors include Kenneth D. Westover, John C. Hunter, Martin A. Carrasco, Sudershan Reddy Gondi, Anuj Manandhar, Alok Dhawan, Alok K. Pandey, Scott B. Ficarro, Jarrod A. Marto and Nathanael S. Gray and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and PLoS ONE.

In The Last Decade

Deepak Gurbani

25 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations

2015 520 citations John C. Hunter, Anuj Manandhar et al. Molecular Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Deepak Gurbani United States	20	1.2k	424	287	280	159	25	1.8k
Angelica M. Merlot Australia	21	1.0k 0.8×	631 1.5×	185 0.6×	126 0.5×	255 1.6×	24	2.2k
Malathy P.V. Shekhar United States	28	1.2k 1.0×	812 1.9×	488 1.7×	127 0.5×	117 0.7×	56	2.3k
G. Aaron Hobbs United States	13	1.0k 0.8×	437 1.0×	172 0.6×	112 0.4×	51 0.3×	22	1.6k
Hui Luo China	29	1.3k 1.1×	267 0.6×	777 2.7×	219 0.8×	268 1.7×	74	2.3k
Weihua Jiang China	23	1.2k 1.0×	351 0.8×	557 1.9×	361 1.3×	60 0.4×	52	1.9k
Michelle L. Turski United States	11	645 0.5×	399 0.9×	139 0.5×	130 0.5×	56 0.4×	20	1.6k
Gabriela M. Almeida Portugal	24	806 0.7×	322 0.8×	460 1.6×	84 0.3×	88 0.6×	38	1.6k
Laurent Debüssche France	34	2.2k 1.8×	512 1.2×	185 0.6×	224 0.8×	172 1.1×	75	2.7k
Xiaomin Wang China	23	809 0.7×	226 0.5×	333 1.2×	205 0.7×	46 0.3×	48	1.6k
James P. Thomas United States	17	781 0.7×	350 0.8×	234 0.8×	65 0.2×	143 0.9×	30	1.6k

Countries citing papers authored by Deepak Gurbani

Since Specialization

Citations

This map shows the geographic impact of Deepak Gurbani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deepak Gurbani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deepak Gurbani more than expected).

Fields of papers citing papers by Deepak Gurbani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deepak Gurbani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deepak Gurbani. The network helps show where Deepak Gurbani may publish in the future.

Co-authorship network of co-authors of Deepak Gurbani

This figure shows the co-authorship network connecting the top 25 collaborators of Deepak Gurbani. A scholar is included among the top collaborators of Deepak Gurbani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deepak Gurbani. Deepak Gurbani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Park, Jung Mi, Seung Wook Yang, Wei Zhuang, et al.. (2021). The nonreceptor tyrosine kinase SRMS inhibits autophagy and promotes tumor growth by phosphorylating the scaffolding protein FKBP51. PLoS Biology. 19(6). e3001281–e3001281. 9 indexed citations

Gurbani, Deepak, Guangyan Du, Nathaniel J. Henning, et al.. (2020). Structure and Characterization of a Covalent Inhibitor of Src Kinase. Frontiers in Molecular Biosciences. 7. 81–81. 21 indexed citations

Hughes, Philip F., et al.. (2019). A highly selective inhibitor of interleukin-1 receptor–associated kinases 1/4 (IRAK-1/4) delineates the distinct signaling roles of IRAK-1/4 and the TAK1 kinase. Journal of Biological Chemistry. 295(6). 1565–1574. 19 indexed citations

Bera, Asim K., Jia Lu, Thomas E. Wales, et al.. (2019). Structural basis of the atypical activation mechanism of KRASV14I. Journal of Biological Chemistry. 294(38). 13964–13972. 20 indexed citations

Gurbani, Deepak, Guangyan Du, Robert A. Everley, et al.. (2019). Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome. Cell chemical biology. 26(6). 818–829.e9. 51 indexed citations

Totzke, Juliane, Deepak Gurbani, Rene Raphemot, et al.. (2017). Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-α Inhibition for Cancer and Autoimmune Disease. Cell chemical biology. 24(8). 1029–1039.e7. 106 indexed citations

Yang, Yan, Lili Ding, Qun Hu, et al.. (2017). MicroRNA-218 functions as a tumor suppressor in lung cancer by targeting IL-6/STAT3 and negatively correlates with poor prognosis. Molecular Cancer. 16(1). 141–141. 121 indexed citations

Tan, Li, Deepak Gurbani, Ellen Weisberg, et al.. (2016). Structure-guided development of covalent TAK1 inhibitors. Bioorganic & Medicinal Chemistry. 25(3). 838–846. 26 indexed citations

Harshbarger, Wayne, Sudershan Reddy Gondi, Scott B. Ficarro, et al.. (2016). Structural and Biochemical Analyses Reveal the Mechanism of Glutathione S-Transferase Pi 1 Inhibition by the Anti-cancer Compound Piperlongumine. Journal of Biological Chemistry. 292(1). 112–120. 72 indexed citations

10.

Tan, Li, Deepak Gurbani, Ellen Weisberg, et al.. (2016). Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. Bioorganic & Medicinal Chemistry. 25(4). 1320–1328. 18 indexed citations

11.

Hunter, John C., Anuj Manandhar, Martin A. Carrasco, et al.. (2015). Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations. Molecular Cancer Research. 13(9). 1325–1335. 520 indexed citations breakdown →

12.

Lim, Sang Min, Ting Xie, Kenneth D. Westover, et al.. (2015). Development of small molecules targeting the pseudokinase Her3. Bioorganic & Medicinal Chemistry Letters. 25(16). 3382–3389. 52 indexed citations

13.

Lu, Jia, John C. Hunter, Anuj Manandhar, Deepak Gurbani, & Kenneth D. Westover. (2015). Structural dataset for the fast-exchanging KRAS G13D. Data in Brief. 5. 572–578. 5 indexed citations

14.

Xie, Ting, Sang Min Lim, Kenneth D. Westover, et al.. (2014). Pharmacological targeting of the pseudokinase Her3. Nature Chemical Biology. 10(12). 1006–1012. 162 indexed citations

15.

Pandey, Alok K., Deepak Gurbani, Kainat Khan, et al.. (2013). In-Vivo Efficacy of Compliant 3D Nano-Composite in Critical-Size Bone Defect Repair: a Six Month Preclinical Study in Rabbit. PLoS ONE. 8(10). e77578–e77578. 19 indexed citations

16.

Gurbani, Deepak, Vandna Kukshal, Ashutosh Kumar, et al.. (2012). Mechanism of Inhibition of the ATPase Domain of Human Topoisomerase IIα by 1,4-Benzoquinone, 1,2-Naphthoquinone, 1,4-Naphthoquinone, and 9,10-Phenanthroquinone. Toxicological Sciences. 126(2). 372–390. 36 indexed citations

17.

Gurbani, Deepak, Ritesh K. Shukla, Alok K. Pandey, & Alok Dhawan. (2011). Stable Metal Oxide Nanoparticle Formulation for Toxicity Studies. Journal of Biomedical Nanotechnology. 7(1). 104–105. 2 indexed citations

18.

Gupta, Shishir K., et al.. (2011). Interaction of C₆₀ Fullerene with the Proteins Involved in DNA Mismatch Repair Pathway. Journal of Biomedical Nanotechnology. 7(1). 179–180. 14 indexed citations

19.

Gurbani, Deepak, et al.. (2011). C₆₀-Fullerene Binds with the ATP Binding Domain of Human DNA Topoiosmerase II Alpha. Journal of Biomedical Nanotechnology. 7(1). 177–178. 20 indexed citations

20.

Pandey, Alok K., Deepak Gurbani, Mahima Bajpayee, et al.. (2008). In silico studies with human DNA topoisomerase-II alpha to unravel the mechanism of in vitro genotoxicity of benzene and its metabolites. Mutation research. Fundamental and molecular mechanisms of mutagenesis. 661(1-2). 57–70. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact